Phase I trial of EPZ 6438 in children with INI1-deficient solid tumours, including malignant rhabdoid tumours.

Trial Profile

Phase I trial of EPZ 6438 in children with INI1-deficient solid tumours, including malignant rhabdoid tumours.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications Rhabdoid tumour; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Epizyme
  • Most Recent Events

    • 04 Aug 2017 According to an Epizyme media release, the company initiated the dose-expansion portion of the study in Jul 2017.
    • 09 Nov 2015 Interim results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
    • 26 Sep 2015 Planned number of patients changed from 40 to 51, as per Epizyme media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top